Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alex Toker, PH.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA200671 (TOKER, ALEX) May 9, 2016 - Apr 30, 2021
    NIH/NCI
    Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
    Role: Principal Investigator
  2. R21CA181143 (TOKER, ALEX) Jan 1, 2014 - Dec 31, 2015
    NIH/NCI
    Identifying lincRNAs that Mediate PI 3 Kinase Dependent Breast Cancer
    Role: Principal Investigator
  3. R01CA177910 (TOKER, ALEX) Jul 16, 2013 - May 31, 2018
    NIH/NCI
    Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
    Role: Principal Investigator
  4. R13CA130395 (TOKER, ALEX) Jul 1, 2007 - Jun 30, 2008
    NIH/NCI
    FASEB Summer Research Conference on Lipid Signaling Pathways in Cancer
    Role: Principal Investigator
  5. R01CA122099 (TOKER, ALEX) Apr 1, 2007 - Feb 29, 2012
    NIH/NCI
    The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Toker A, Dibble CC. PI 3-Kinase Signaling: AKTing up inside the Cell. Mol Cell. 2018 Sep 20; 71(6):875-876. PMID: 30241602.
    View in: PubMed
  2. Clement E, Inuzuka H, Nihira NT, Wei W, Toker A. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. Sci Signal. 2018 Mar 13; 11(521). PMID: 29535262.
    View in: PubMed
  3. Lien EC, Ghisolfi L, Geck RC, Asara JM, Toker A. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT. Sci Signal. 2017 Dec 19; 10(510). PMID: 29259101.
    View in: PubMed
  4. Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov. 2018 Mar; 8(3):354-369. PMID: 29203461.
    View in: PubMed
  5. Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017 04 20; 169(3):381-405. PMID: 28431241.
    View in: PubMed
  6. Ruzzene M, Bertacchini J, Toker A, Marmiroli S. Cross-talk between the CK2 and AKT signaling pathways in cancer. Adv Biol Regul. 2017 05; 64:1-8. PMID: 28373060.
    View in: PubMed
  7. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017 04; 45:62-71. PMID: 28343126.
    View in: PubMed
  8. Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2017 04; 7(4):391-399. PMID: 28255083.
    View in: PubMed
  9. Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal. 2017 02 21; 10(467). PMID: 28223411.
    View in: PubMed
  10. Shimizu K, Fukushima H, Ogura K, Lien EC, Nihira NT, Zhang J, North BJ, Guo A, Nagashima K, Nakagawa T, Hoshikawa S, Watahiki A, Okabe K, Yamada A, Toker A, Asara JM, Fukumoto S, Nakayama KI, Nakayama K, Inuzuka H, Wei W. The SCFß-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal. 2017 01 03; 10(460). PMID: 28049764.
    View in: PubMed
  11. Henry WS, Hendrickson DG, Beca F, Glass B, Lindahl-Allen M, He L, Ji Z, Struhl K, Beck AH, Rinn JL, Toker A. LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer. Oncotarget. 2016 Dec 13; 7(50):81981-81994. PMID: 27626181.
    View in: PubMed
  12. Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Res. 2017 02 01; 77(3):790-801. PMID: 27940576.
    View in: PubMed
  13. Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang L, Yuan M, Novak J, Cheng JQ, Toker A, Signoretti S, Zhang Q, Asara JM, Kaelin WG, Wei W. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016 08 26; 353(6302):929-32. PMID: 27563096.
    View in: PubMed
  14. Zhang J, Xu K, Liu P, Geng Y, Wang B, Gan W, Guo J, Wu F, Chin YR, Berrios C, Lien EC, Toker A, DeCaprio JA, Sicinski P, Wei W. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. Mol Cell. 2016 06 16; 62(6):929-942. PMID: 27237051; PMCID: PMC4912424 [Available on 06/16/17].
  15. Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A. Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat Cell Biol. 2016 05; 18(5):572-8. PMID: 27088857; PMCID: PMC4848114 [Available on 10/18/16].
  16. Mancini ML, Lien EC, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016 Apr 05; 7(14):17301-13. PMID: 27004402; PMCID: PMC4951213.
  17. Geck RC, Toker A. Nonessential amino acid metabolism in breast cancer. Adv Biol Regul. 2016 09; 62:11-17. PMID: 26838061.
    View in: PubMed
  18. Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discov. 2015 Nov; 5(11):1194-209. PMID: 26293922; PMCID: PMC4631654.
  19. Toker A, Rameh L. PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K? Cancer Cell. 2015 Aug 10; 28(2):143-5. PMID: 26267528.
    View in: PubMed
  20. Brown KK, Montaser-Kouhsari L, Beck AH, Toker A. MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. Cell Rep. 2015 Jun 09; 11(9):1358-66. PMID: 26027929; PMCID: PMC4464897.
  21. Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, Luo HR, Beck AH, Toker A. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol. 2015 Jun; 9(6):1140-54. PMID: 25735562; PMCID: PMC4439371.
  22. Brown KK, Toker A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 2015; 7:13. PMID: 25750731; PMCID: PMC4335789.
  23. Gasser JA, Inuzuka H, Lau AW, Wei W, Beroukhim R, Toker A. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell. 2014 Nov 20; 56(4):595-607. PMID: 25458846; PMCID: PMC4255362.
  24. Clark AR, Toker A. Signalling specificity in the Akt pathway in breast cancer. Biochem Soc Trans. 2014 Oct; 42(5):1349-55. PMID: 25233414.
    View in: PubMed
  25. Chin YR, Yuan X, Balk SP, Toker A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014 Aug; 4(8):942-55. PMID: 24838891; PMCID: PMC4125464.
  26. Toker A, Chin YR. Akt-ing up on SRPK1: oncogene or tumor suppressor? Mol Cell. 2014 May 08; 54(3):329-30. PMID: 24813709; PMCID: PMC4089875.
  27. Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul. 2014 May; 55:28-38. PMID: 24794538; PMCID: PMC4062840.
  28. Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature. 2014 Apr 24; 508(7497):541-5. PMID: 24670654; PMCID: PMC4076493.
  29. Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res. 2014 Feb 01; 74(3):964-73. PMID: 24335962; PMCID: PMC3946502.
  30. Elloul S, Kedrin D, Knoblauch NW, Beck AH, Toker A. The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration. Mol Cancer Res. 2014 Mar; 12(3):464-76. PMID: 24269953; PMCID: PMC3962723.
  31. White CD, Toker A. Using phospho-motif antibodies to determine kinase substrates. Curr Protoc Mol Biol. 2013 Jan; Chapter 18:Unit 18.20.. PMID: 23288461.
    View in: PubMed
  32. Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE. RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res. 2013 Jan 01; 73(1):50-61. PMID: 23135917; PMCID: PMC4201498.
  33. Christoforides C, Rainero E, Brown KK, Norman JC, Toker A. PKD controls avß3 integrin recycling and tumor cell invasive migration through its substrate Rabaptin-5. Dev Cell. 2012 Sep 11; 23(3):560-72. PMID: 22975325; PMCID: PMC3443396.
  34. Inuzuka H, Gao D, Finley LW, Yang W, Wan L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, Wang Z, Gygi SP, Nakayama K, Teruya-Feldstein J, Toker A, Haigis MC, Pandolfi PP, Wei W. Acetylation-dependent regulation of Skp2 function. Cell. 2012 Jul 06; 150(1):179-93. PMID: 22770219; PMCID: PMC3595190.
  35. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9. PMID: 22722202; PMCID: PMC4148686.
  36. Toker A. Phosphoinositide 3-kinases-a historical perspective. Subcell Biochem. 2012; 58:95-110. PMID: 22403075.
    View in: PubMed
  37. Toker A. Achieving specificity in Akt signaling in cancer. Adv Biol Regul. 2012 Jan; 52(1):78-87. PMID: 21986444; PMCID: PMC3614006.
  38. Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J. 2011 Nov 15; 440(1):157-66. PMID: 21871017; PMCID: PMC3204871.
  39. Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW, Wei W. mTOR drives its own activation via SCF(ßTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell. 2011 Oct 21; 44(2):290-303. PMID: 22017875; PMCID: PMC3229299.
  40. Chin YR, Toker A. Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr. 2011 May-Jun; 5(3):211-4. PMID: 21519185; PMCID: PMC3210203.
  41. Chin YR, Toker A. Akt2 regulates expression of the actin-bundling protein palladin. FEBS Lett. 2010 Dec 01; 584(23):4769-74. PMID: 21050850; PMCID: PMC2997733.
  42. Gao D, Wan L, Inuzuka H, Berg AH, Tseng A, Zhai B, Shaik S, Bennett E, Tron AE, Gasser JA, Lau A, Gygi SP, Harper JW, DeCaprio JA, Toker A, Wei W. Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol Cell. 2010 Sep 10; 39(5):797-808. PMID: 20832730; PMCID: PMC2939073.
  43. Fry JL, Toker A. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 2010 Oct 15; 70(20):8187-98. PMID: 20736367; PMCID: PMC2955804.
  44. Chin YR, Toker A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell. 2010 May 14; 38(3):333-44. PMID: 20471940; PMCID: PMC2872630.
  45. Nhek S, Ngo M, Yang X, Ng MM, Field SJ, Asara JM, Ridgway ND, Toker A. Regulation of oxysterol-binding protein Golgi localization through protein kinase D-mediated phosphorylation. Mol Biol Cell. 2010 Jul 01; 21(13):2327-37. PMID: 20444975.
    View in: PubMed
  46. Toker A. TTC3 ubiquitination terminates Akt-ivation. Dev Cell. 2009 Dec; 17(6):752-4. PMID: 20059946.
    View in: PubMed
  47. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer. 2009 Nov; 9(11):810-20. PMID: 19851316; PMCID: PMC2866640.
  48. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res. 2009 Aug 01; 69(15):6299-306. PMID: 19602588; PMCID: PMC2727605.
  49. Storz P, Döppler H, Copland JA, Simpson KJ, Toker A. FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol. 2009 Sep; 29(18):4906-17. PMID: 19564415; PMCID: PMC2738298.
  50. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009 Apr; 11(4):397-408. PMID: 19270695; PMCID: PMC2910589.
  51. Yoeli-Lerner M, Chin YR, Hansen CK, Toker A. Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res. 2009 Mar; 7(3):425-32. PMID: 19258413; PMCID: PMC2667900.
  52. Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 2009 Apr; 21(4):470-6. PMID: 19110052; PMCID: PMC2719559.
  53. Watkins JL, Lewandowski KT, Meek SE, Storz P, Toker A, Piwnica-Worms H. Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association. Proc Natl Acad Sci U S A. 2008 Nov 25; 105(47):18378-83. PMID: 19011111; PMCID: PMC2587537.
  54. Toker A. mTOR and Akt signaling in cancer: SGK cycles in. Mol Cell. 2008 Jul 11; 31(1):6-8. PMID: 18614042.
    View in: PubMed
  55. Toker A. Akt signaling: a damaging interaction makes good. Trends Biochem Sci. 2008 Aug; 33(8):356-9. PMID: 18585043.
    View in: PubMed
  56. Kunkel MT, Toker A, Tsien RY, Newton AC. Calcium-dependent regulation of protein kinase D revealed by a genetically encoded kinase activity reporter. J Biol Chem. 2007 Mar 02; 282(9):6733-42. PMID: 17189263; PMCID: PMC2921767.
  57. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006 Apr 15; 66(8):3963-6. PMID: 16618711.
    View in: PubMed
  58. Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006 Mar; 5(6):603-5. PMID: 16582622.
    View in: PubMed
  59. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem. 2006 May 05; 281(18):12210-7. PMID: 16505480.
    View in: PubMed
  60. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 2005 Nov 23; 20(4):539-50. PMID: 16307918.
    View in: PubMed
  61. Storz P, Döppler H, Toker A. Protein kinase D mediates mitochondrion-to-nucleus signaling and detoxification from mitochondrial reactive oxygen species. Mol Cell Biol. 2005 Oct; 25(19):8520-30. PMID: 16166634; PMCID: PMC1265746.
  62. Hausser A, Storz P, Märtens S, Link G, Toker A, Pfizenmaier K. Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. Nat Cell Biol. 2005 Sep; 7(9):880-6. PMID: 16100512; PMCID: PMC1458033.
  63. Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, Toker A. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005 Jun 01; 65(11):4728-38. PMID: 15930291.
    View in: PubMed
  64. Toker A. The biology and biochemistry of diacylglycerol signalling. Meeting on molecular advances in diacylglycerol signalling. EMBO Rep. 2005 Apr; 6(4):310-4. PMID: 15791268; PMCID: PMC1299288.
  65. Storz P, Döppler H, Ferran C, Grey ST, Toker A. Functional dichotomy of A20 in apoptotic and necrotic cell death. Biochem J. 2005 Apr 01; 387(Pt 1):47-55. PMID: 15527421; PMCID: PMC1134931.
  66. Döppler H, Storz P, Li J, Comb MJ, Toker A. A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. J Biol Chem. 2005 Apr 15; 280(15):15013-9. PMID: 15728188.
    View in: PubMed
  67. Hodges RR, Raddassi I, Zoukhri D, Toker A, Kazlauskas A, Dartt DA. Effect of overexpression of constitutively active PKCalpha on rat lacrimal gland protein secretion. Invest Ophthalmol Vis Sci. 2004 Nov; 45(11):3974-81. PMID: 15505044.
    View in: PubMed
  68. Hutti JE, Jarrell ET, Chang JD, Abbott DW, Storz P, Toker A, Cantley LC, Turk BE. A rapid method for determining protein kinase phosphorylation specificity. Nat Methods. 2004 Oct; 1(1):27-9. PMID: 15782149.
    View in: PubMed
  69. Storz P, Döppler H, Toker A. Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappaB. Mol Pharmacol. 2004 Oct; 66(4):870-9. PMID: 15226414.
    View in: PubMed
  70. Storz P, Döppler H, Toker A. Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling. Mol Cell Biol. 2004 Apr; 24(7):2614-26. PMID: 15024053; PMCID: PMC371115.
  71. Storz P, Döppler H, Johannes FJ, Toker A. Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain leads to activation. J Biol Chem. 2003 May 16; 278(20):17969-76. PMID: 12637538.
    View in: PubMed
  72. Storz P, Toker A. Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway. EMBO J. 2003 Jan 02; 22(1):109-20. PMID: 12505989; PMCID: PMC140053.
  73. Storz P, Toker A. NF-kappaB signaling--an alternate pathway for oxidative stress responses. Cell Cycle. 2003 Jan-Feb; 2(1):9-10. PMID: 12695674.
    View in: PubMed
  74. Toker A. Identifying protein kinase C substrates: an introduction. Methods Mol Biol. 2003; 233:247-51. PMID: 12840512.
    View in: PubMed
  75. Toker A. Genetic manipulation of protein kinase C in vivo. Methods Mol Biol. 2003; 233:475-89. PMID: 12840530.
    View in: PubMed
  76. Toker A. PDK-1 and protein kinase C phosphorylation. Methods Mol Biol. 2003; 233:171-89. PMID: 12840507.
    View in: PubMed
  77. Jauliac S, López-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002 Jul; 4(7):540-4. PMID: 12080349.
    View in: PubMed
  78. Toker A. Phosphoinositides and signal transduction. Cell Mol Life Sci. 2002 May; 59(5):761-79. PMID: 12088277.
    View in: PubMed
  79. Cenni V, Döppler H, Sonnenburg ED, Maraldi N, Newton AC, Toker A. Regulation of novel protein kinase C epsilon by phosphorylation. Biochem J. 2002 May 01; 363(Pt 3):537-45. PMID: 11964154; PMCID: PMC1222506.
  80. Storz P, Toker A. 3'-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci. 2002 Apr 01; 7:d886-902. PMID: 11897568.
    View in: PubMed
  81. Hodges RR, Kazlauskas A, Toker A, Dartt DA. Effect of overexpression of protein kinase C alpha on rat lacrimal gland protein secretion. Adv Exp Med Biol. 2002; 506(Pt A):237-41. PMID: 12613914.
    View in: PubMed
  82. Lian JP, Toker A, Badwey JA. Phosphorylation of the activation loop of gamma p21-activated kinase (gamma-Pak) and related kinases (MSTs) in normal and stressed neutrophils. J Immunol. 2001 May 15; 166(10):6349-57. PMID: 11342659.
    View in: PubMed
  83. Hoffmeister KM, Falet H, Toker A, Barkalow KL, Stossel TP, Hartwig JH. Mechanisms of cold-induced platelet actin assembly. J Biol Chem. 2001 Jul 06; 276(27):24751-9. PMID: 11328807.
    View in: PubMed
  84. Gao T, Toker A, Newton AC. The carboxyl terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, PDK-1. J Biol Chem. 2001 Jun 01; 276(22):19588-96. PMID: 11376011.
    View in: PubMed
  85. Lian JP, Crossley L, Zhan Q, Huang R, Coffer P, Toker A, Robinson D, Badwey JA. Antagonists of calcium fluxes and calmodulin block activation of the p21-activated protein kinases in neutrophils. J Immunol. 2001 Feb 15; 166(4):2643-50. PMID: 11160327.
    View in: PubMed
  86. Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell. 2000 Oct 13; 103(2):185-8. PMID: 11057891.
    View in: PubMed
  87. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol. 2000 Apr; 57(4):652-8. PMID: 10727509.
    View in: PubMed
  88. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem. 2000 Mar 24; 275(12):8271-4. PMID: 10722653.
    View in: PubMed
  89. Balciunaite E, Jones S, Toker A, Kazlauskas A. PDGF initiates two distinct phases of protein kinase C activity that make unequal contributions to the G0 to S transition. Curr Biol. 2000 Mar 09; 10(5):261-7. PMID: 10712903.
    View in: PubMed
  90. Rabinovitz I, Toker A, Mercurio AM. Protein kinase C-dependent mobilization of the alpha6beta4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J Cell Biol. 1999 Sep 06; 146(5):1147-60. PMID: 10477766; PMCID: PMC2169473.
  91. Paradis S, Ailion M, Toker A, Thomas JH, Ruvkun G. A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 1999 Jun 01; 13(11):1438-52. PMID: 10364160; PMCID: PMC316759.
  92. Jones SM, Klinghoffer R, Prestwich GD, Toker A, Kazlauskas A. PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1. Curr Biol. 1999 May 20; 9(10):512-21. PMID: 10339426.
    View in: PubMed
  93. Romanelli A, Martin KA, Toker A, Blenis J. p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol. 1999 Apr; 19(4):2921-8. PMID: 10082559; PMCID: PMC84086.
  94. Robinson D, Huang R, Lian JP, Toker A, Badwey JA. Functions of the p21-activated protein kinases (Paks) in neutrophils and their regulation by complex lipids. Adv Exp Med Biol. 1999; 469:385-90. PMID: 10667357.
    View in: PubMed
  95. Toker A. Signaling through protein kinase C. Front Biosci. 1998 Nov 01; 3:D1134-47. PMID: 9792904.
    View in: PubMed
  96. Nishikawa K, Toker A, Wong K, Marignani PA, Johannes FJ, Cantley LC. Association of protein kinase Cmu with type II phosphatidylinositol 4-kinase and type I phosphatidylinositol-4-phosphate 5-kinase. J Biol Chem. 1998 Sep 04; 273(36):23126-33. PMID: 9722541.
    View in: PubMed
  97. Toker A. The synthesis and cellular roles of phosphatidylinositol 4,5-bisphosphate. Curr Opin Cell Biol. 1998 Apr; 10(2):254-61. PMID: 9561850.
    View in: PubMed
  98. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell. 1997 Dec 26; 91(7):949-60. PMID: 9428518.
    View in: PubMed
  99. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature. 1997 Jun 12; 387(6634):673-6. PMID: 9192891.
    View in: PubMed
  100. Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3016-21. PMID: 9096338; PMCID: PMC20314.
  101. Derman MP, Toker A, Hartwig JH, Spokes K, Falck JR, Chen CS, Cantley LC, Cantley LG. The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C. J Biol Chem. 1997 Mar 07; 272(10):6465-70. PMID: 9045671.
    View in: PubMed
  102. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997 Jan 31; 275(5300):665-8. PMID: 9005852.
    View in: PubMed
  103. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem. 1997 Jan 10; 272(2):952-60. PMID: 8995387.
    View in: PubMed
  104. Zoukhri D, Hodges RR, Sergheraert C, Toker A, Dartt DA. Lacrimal gland PKC isoforms are differentially involved in agonist-induced protein secretion. Am J Physiol. 1997 Jan; 272(1 Pt 1):C263-9. PMID: 9038832.
    View in: PubMed
  105. Hartwig JH, Kung S, Kovacsovics T, Janmey PA, Cantley LC, Stossel TP, Toker A. D3 phosphoinositides and outside-in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13-acetate. J Biol Chem. 1996 Dec 20; 271(51):32986-93. PMID: 8955143.
    View in: PubMed
  106. Toker A, Bachelot C, Chen CS, Falck JR, Hartwig JH, Cantley LC, Kovacsovics TJ. Phosphorylation of the platelet p47 phosphoprotein is mediated by the lipid products of phosphoinositide 3-kinase. J Biol Chem. 1995 Dec 08; 270(49):29525-31. PMID: 7493994.
    View in: PubMed
  107. Kapeller R, Toker A, Cantley LC, Carpenter CL. Phosphoinositide 3-kinase binds constitutively to alpha/beta-tubulin and binds to gamma-tubulin in response to insulin. J Biol Chem. 1995 Oct 27; 270(43):25985-91. PMID: 7592789.
    View in: PubMed
  108. Hartwig JH, Bokoch GM, Carpenter CL, Janmey PA, Taylor LA, Toker A, Stossel TP. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell. 1995 Aug 25; 82(4):643-53. PMID: 7664343.
    View in: PubMed
  109. Soltoff SP, Toker A. Carbachol, substance P, and phorbol ester promote the tyrosine phosphorylation of protein kinase C delta in salivary gland epithelial cells. J Biol Chem. 1995 Jun 02; 270(22):13490-5. PMID: 7539427.
    View in: PubMed
  110. Kovacsovics TJ, Bachelot C, Toker A, Vlahos CJ, Duckworth B, Cantley LC, Hartwig JH. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem. 1995 May 12; 270(19):11358-66. PMID: 7744773.
    View in: PubMed
  111. Toker A, Meyer M, Reddy KK, Falck JR, Aneja R, Aneja S, Parra A, Burns DJ, Ballas LM, Cantley LC. Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5-P3. J Biol Chem. 1994 Dec 23; 269(51):32358-67. PMID: 7798235.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Toker's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (498)
Explore
_
Co-Authors (54)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.